FDA Approval Expands Enspryng’s Thyroid Eye Disease Opportunity for Roche-Backed Genentech
The FDA approved Enspryng for thyroid eye disease, giving Genentech and Roche a potential new avenue for specialty pharmaceutical growth.
Potential J&J Orthopedics Spinoff Puts Conglomerate Strategy and Valuation in Focus
A reported J&J plan to spin out its hips-and-knees unit could reshape the valuation and capital-allocation debate around $JNJ.
Galderma’s $1.5 Billion ZO Skin Health Purchase Signals Continued Aesthetics Consolidation
Galderma’s $1.5 billion cash acquisition of ZO Skin Health highlights consolidation in dermatology and a notable healthcare private-equity e…
Labcorp’s $872 Million BioReference Deal Puts Diagnostics M&A in Focus
Labcorp’s agreement to acquire select BioReference assets from OPKO highlights diagnostics consolidation, valuation questions and deal-closi…
Aquestive’s Anaphylm NDA Resubmission Clears FDA Filing Hurdle, Setting Up AQST Catalyst
Aquestive’s accepted Anaphylm NDA resubmission gives AQST a key regulatory catalyst, with traders watching volatility ahead of the FDA decis…
Labcorp’s $872M BioReference Deal Expands Diagnostics Footprint as OPKO Reshapes Portfolio
Labcorp’s proposed BioReference asset deal could expand its diagnostics capacity while giving OPKO Health a sharper portfolio focus.
Ultragenyx’s $203 Million Voucher Sale Adds a Non-Dilutive Cash Catalyst
Ultragenyx’s planned $203 million FDA voucher sale gives $RARE a potential cash catalyst without issuing new shares.
AbbVie Stock Reaches Record High After FDA Approves Parkinson’s Drug Juvmo
AbbVie’s $283.44 record high and FDA approval of Juvmo strengthen the company’s pipeline narrative without offering a forecast for sales or …
J&J Weighs Orthopedics Spinoff as Investors Reassess Its Portfolio and Valuation
Johnson & Johnson is reportedly leaning toward spinning out its hips-and-knees business, putting portfolio strategy and valuation in focus.
Ultragenyx’s $203 Million Voucher Sale Sets a New Cash Benchmark for Biotech
Ultragenyx’s agreed $203 million voucher sale could strengthen its balance sheet and give biotech investors a benchmark for non-dilutive fun…
Galderma’s $1.5 Billion ZO Skin Health Deal Signals More Consolidation in Dermatology
Galderma’s $1.5 billion cash purchase of ZO Skin Health highlights continued consolidation across dermatology, skincare and medical aestheti…
Vaxcyte Raises $1.15 Billion to Advance VAX-31 as PCVX Shares Surge
Vaxcyte’s $1.15 billion public offering strengthens funding for VAX-31 while putting shareholder dilution in sharper focus.











